Association Between Genotype and Phenotype in Consecutive Unrelated Individuals With Retinoblastoma.
Adolescent
Adult
Child
Child, Preschool
DNA, Neoplasm
/ genetics
Female
Genetic Association Studies
Genetic Predisposition to Disease
Germ-Line Mutation
Humans
Infant
Infant, Newborn
Male
Penetrance
Retinal Neoplasms
/ genetics
Retinoblastoma
/ genetics
Retinoblastoma Binding Proteins
/ genetics
Retrospective Studies
Ubiquitin-Protein Ligases
/ genetics
Young Adult
Journal
JAMA ophthalmology
ISSN: 2168-6173
Titre abrégé: JAMA Ophthalmol
Pays: United States
ID NLM: 101589539
Informations de publication
Date de publication:
01 08 2020
01 08 2020
Historique:
pubmed:
20
6
2020
medline:
23
1
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
Retinoblastoma (RB) is the most common pediatric intraocular neoplasm. RB is a complex model in which atypical pathogenic variants, modifier genes, imprinting, and mosaicism are known to be associated with the phenotype. In-depth understanding of RB therefore requires large genotype-phenotype studies. To assess the association between genotype and phenotype in patients with RB. This single-center, retrospective cohort study, conducted from January 1, 2000, to September 30, 2017, enrolled 1404 consecutive ascertained patients with RB who consulted an oncogeneticist. All patients had their genotype and phenotype recorded. Statistical analysis was performed from July 1, 2018, to December 31, 2018. RB1 germline and somatic pathogenic variant types, family history, and disease presentation characteristics (ie, age at diagnosis, sex, laterality, and International Intraocular Retinoblastoma Classification group). Among 1404 patients with RB (734 [52.3%] female; mean [SD] age, 20.2 [21.2] months), 866 cases (61.7%) were unilateral and 538 cases (38.3%) were bilateral. Loss of function variants were found throughout the coding sequence, with 259 of 272 (95.2%) somatic pathogenic variants and 537 of 606 (88.6%) germline pathogenic variants (difference, 6.6%; 95% CI, 4.0%-9.2%; P < .001) after excluding tumor-specific pathogenic variants (ie, promoter methylation and loss of heterozygosity); a novel low-penetrance region was identified in exon 24. Compared with germline pathogenic variants estimated to retain RB protein expression, germline pathogenic variants estimated to abrogate RB protein expression were associated with an earlier mean (SD) age at diagnosis (12.3 [11.3] months among 457 patients vs 16.3 [13.2] months among 55 patients; difference, 4 months; 95% CI, 1.9-6.1 months; P = .01), more frequent bilateral involvement (84.2% among 452 patients vs 65.2% among 45 patients; difference, 18.9%; 95% CI, 14.5%-23.3%; P < .001), and more advanced International Intraocular Retinoblastoma Classification group (85.3% among 339 patients vs 73.9% among 34 patients; difference: 11.4%; 95% CI, 6.5%-16.3%; P = .047). Among the 765 nongermline carriers of an RB1 pathogenic variant, most were female (419 females [54.8%] vs 346 males [45.2%]; P = .008), and males were more likely to have bilateral RB (23 males [71.4%] vs 12 females [34.3%]; P = .01). These results suggest that RB risk is associated with the germline pathogenic variant and with maintenance of RB protein and that there is a sex-linked mechanism for nongermline carriers.
Identifiants
pubmed: 32556071
pii: 2766938
doi: 10.1001/jamaophthalmol.2020.2100
pmc: PMC7303903
doi:
Substances chimiques
DNA, Neoplasm
0
RB1 protein, human
0
Retinoblastoma Binding Proteins
0
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
843-850Références
Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12036-40
pubmed: 9342358
Int J Cancer. 2001 Aug 1;93(3):333-8
pubmed: 11433396
Hum Mol Genet. 2014 Oct 1;23(19):5243-50
pubmed: 24858910
PLoS One. 2017 Jun 2;12(6):e0178776
pubmed: 28575107
Front Pharmacol. 2019 Feb 27;10:121
pubmed: 30873022
Ophthalmol Clin North Am. 2005 Mar;18(1):41-53, viii
pubmed: 15763190
Prenat Diagn. 2011 Nov;31(11):1106-8
pubmed: 21905051
Hum Mutat. 2004 Feb;23(2):193-202
pubmed: 14722923
Am J Med Genet C Semin Med Genet. 2004 Aug 15;129C(1):23-8
pubmed: 15264269
Eur J Hum Genet. 2007 Apr;15(4):473-7
pubmed: 17299438
Hum Mutat. 2007 Mar;28(3):284-93
pubmed: 17096365
Mol Vis. 2014 Apr 25;20:545-52
pubmed: 24791139
Nat Rev Cancer. 2003 Feb;3(2):130-8
pubmed: 12563312
J Natl Cancer Inst. 2010 Dec 1;102(23):1805-8
pubmed: 21051655
Expert Opin Biol Ther. 2017 Feb;17(2):225-236
pubmed: 27936976
Hum Mutat. 2001 May;17(5):412-22
pubmed: 11317357
J Natl Cancer Inst. 2019 Sep 1;111(9):961-969
pubmed: 30698734
Nature. 1986 Oct 16-22;323(6089):643-6
pubmed: 2877398
Br J Ophthalmol. 2009 Jan;93(1):21-3
pubmed: 18621794
Clin Epigenetics. 2016 Jan 08;8:1
pubmed: 26753011
J Clin Oncol. 2005 Apr 1;23(10):2272-9
pubmed: 15800318
Genes Dev. 2016 Jul 1;30(13):1492-502
pubmed: 27401552
Br J Ophthalmol. 2009 Jan;93(1):33-7
pubmed: 18838413
J Clin Oncol. 2016 Sep 10;34(26):3183-8
pubmed: 27382102
Arch Ophthalmol. 2001 Nov;119(11):1699-704
pubmed: 11709023
Hum Mutat. 2016 Sep;37(9):865-76
pubmed: 27328919
PLoS Genet. 2016 Feb 29;12(2):e1005888
pubmed: 26925970
Hum Mutat. 2007 Feb;28(2):159-67
pubmed: 16988938
PLoS One. 2013 Nov 25;8(11):e81502
pubmed: 24282601
Eur J Cancer. 2006 Sep;42(13):2092-102
pubmed: 16919773
Am J Hum Genet. 2003 Feb;72(2):253-69
pubmed: 12541220
Ophthalmology. 2004 Jun;111(6):1228-32
pubmed: 15177976
J Med Genet. 2014 Mar;51(3):208-14
pubmed: 24225018
J Fr Ophtalmol. 2015 Jun;38(6):535-41
pubmed: 25976136
Br J Ophthalmol. 1988 Aug;72(8):576-83
pubmed: 3415951
Br J Ophthalmol. 1997 Jul;81(7):559-62
pubmed: 9290369